Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1894) 1894
Publication (190) 190
Book Review (16) 16
Book Chapter (12) 12
Conference Proceeding (8) 8
Dissertation (3) 3
Government Document (3) 3
Web Resource (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1097) 1097
tumor-regression (1058) 1058
index medicus (813) 813
oncology (763) 763
female (724) 724
cancer (591) 591
male (582) 582
middle aged (512) 512
animals (494) 494
aged (456) 456
tumor regression (436) 436
adult (396) 396
mice (374) 374
surgery (335) 335
chemotherapy (312) 312
treatment outcome (297) 297
neoadjuvant therapy (296) 296
prognosis (282) 282
radiotherapy (271) 271
tumors (268) 268
rectal cancer (251) 251
carcinoma (243) 243
chemoradiotherapy (233) 233
neoplasm staging (228) 228
care and treatment (222) 222
survival (222) 222
therapy (218) 218
preoperative chemoradiotherapy (205) 205
aged, 80 and over (200) 200
rectal neoplasms - pathology (200) 200
immunotherapy (195) 195
rectal neoplasms - therapy (183) 183
apoptosis (176) 176
immunology (168) 168
in-vivo (167) 167
antineoplastic combined chemotherapy protocols - therapeutic use (160) 160
colorectal cancer (160) 160
retrospective studies (158) 158
radiology, nuclear medicine & medical imaging (155) 155
combined modality therapy (153) 153
medicine, research & experimental (152) 152
research (150) 150
analysis (149) 149
disease-free survival (142) 142
chemoradiation (136) 136
expression (132) 132
health aspects (132) 132
melanoma (128) 128
cell biology (127) 127
medicine & public health (126) 126
cell line, tumor (123) 123
pathology (121) 121
adenocarcinoma - pathology (119) 119
neoadjuvant chemoradiotherapy (119) 119
metastasis (111) 111
gastroenterology & hepatology (109) 109
radiation-therapy (109) 109
antineoplastic agents - therapeutic use (106) 106
metastatic melanoma (106) 106
adenocarcinoma - therapy (104) 104
patients (103) 103
biotechnology & applied microbiology (102) 102
neoadjuvant chemotherapy (101) 101
tumor cells, cultured (101) 101
article (99) 99
chemotherapy, adjuvant (99) 99
dendritic cells (99) 99
t-cells (99) 99
mice, inbred c57bl (98) 98
adenocarcinoma (96) 96
esophageal cancer (95) 95
immunohistochemistry (94) 94
survival rate (94) 94
hematology, oncology and palliative medicine (93) 93
biochemistry & molecular biology (92) 92
prognostic-significance (92) 92
time factors (92) 92
regression analysis (91) 91
gene expression (89) 89
genetics & heredity (89) 89
mice, inbred balb c (89) 89
tumor regression grade (89) 89
total mesorectal excision (88) 88
colorectal-cancer (87) 87
lymphocytes (87) 87
adjuvant treatment (85) 85
radiation (85) 85
rectal neoplasms - radiotherapy (83) 83
tumour regression (83) 83
fluorouracil - administration & dosage (82) 82
radiochemotherapy (80) 80
cells (79) 79
neoplasm transplantation (76) 76
rectal neoplasms - surgery (76) 76
esophageal neoplasms - pathology (75) 75
rectal neoplasms - drug therapy (75) 75
breast cancer (74) 74
cancer therapies (72) 72
magnetic resonance imaging (72) 72
t-lymphocytes - immunology (72) 72
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1751) 1751
Chinese (64) 64
German (48) 48
Japanese (19) 19
French (18) 18
Russian (5) 5
Spanish (3) 3
Polish (2) 2
Portuguese (2) 2
Italian (1) 1
Korean (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. The role of innate immunity in spontaneous regression of cancer
by Thomas, J. A and Badini, M
08/2011
Nature has provided us with infections - acute and chronic - and these infections have both harmful and beneficial effects on the human system. Worldwide, a... 
innate immunity | Acute infections | leukocytes | fever | tumor regression
Web Resource
Details down arrow
2. Full Text A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
by Iizuka, A and Nonomura, C and Ashizawa, T and Kondou, R and Ohshima, K and Sugino, T and Mitsuya, K and Hayashi, N and Nakasu, Y and Maruyama, K and Yamaguchi, K and Akiyama, Y
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 9, pp. 2925 - 2934
Purpose: The B7 homolog 4 (B7-H4, VTCN1) is an immune checkpoint molecule that negatively regulates immune responses and is known to be overexpressed in many... 
ONCOLOGY | SAFETY | TUMOR-REGRESSION | RESISTANCE | BLOCKADE | EXPRESSION | B7-H4 | ANTIGEN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Diagnostic radiation-induced regression of a metastatic primary intracranial germinoma: a case report
by Woo, Peter Y. M and Kakaizada, Sofia and Chan, Cherry C. Y and Chan, Timothy S. K and Wong, Hoi-Tung and Chan, Kwong-Yau
British Journal of Neurosurgery, ISSN 0268-8697, 2018, pp. 1 - 4
Pineal region germinomas are sensitive to radiotherapy. Standard neurosurgical management involves obtaining a tissue biopsy and to relieve the often... 
computed tomography | radiotherapy | tumor regression | germinoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A novel and successful strategy to predict survival
by Fleischmann, Achim and Thalmann, George N and Perren, Aurel and Seiler, Roland
American Journal of Surgical Pathology, ISSN 0147-5185, 03/2014, Volume 38, Issue 3, pp. 325 - 332
neoadjuvant chemotherapy | tumor regression grade | bladder cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard’s Tumor Regression Grade (TRG) in gastric adenocarcinoma
by Derieux, Simon and Svrcek, Magali and Manela, Sarah and Lagorce-Pages, Christine and Berger, Anne and André, Thierry and Taieb, Julien and Paye, François and Voron, Thibault
Digestive and Liver Disease, ISSN 1590-8658, 08/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Benefits of adaptive
by Dial, Christian and Weiss, Elisabeth and Siebers, Jeffrey V and Hugo, Geoffrey D
Medical Physics, ISSN 0094-2405, 04/2016, Volume 43, Issue 4, pp. 1787 - 1794
adaptive radiation therapy | tumor regression | non-small-cell lung cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sarcoidosis complicating anti-cytotoxic T-Iymphocyte-associated antigen-4 monoclonal antibody biotherapy
by Tissot, C and Carsin, A and Freymond, N and Pacheco, Y and Devouassoux, G
EUROPEAN RESPIRATORY JOURNAL, ISSN 0903-1936, 01/2013, Volume 41, Issue 1, pp. 246 - 247
LYMPHOCYTE ANTIGEN-4 | AUTOIMMUNITY | RESPIRATORY SYSTEM | TUMOR-REGRESSION | PATIENT | BTNL2 | BLOCKADE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Evaluation of explant responses to STING ligands: Personalized immunosurgical therapy for head and neck squamous cell carcinoma
by Baird, Jason R and Bryan Bell, R and Troesch, Victoria and Friedman, David and Bambina, Shelly and Kramer, Gwen and Blair, Tiffany C and Medler, Terry and Wu, Yaping and Sun, Zhaoyu and de Gruijl, Tanja D and van de Ven, Rieneke and Leidner, Rom S and Crittenden, Marka R and Gough, Michael J
Cancer Research, ISSN 0008-5472, 11/2018, Volume 78, Issue 21, pp. 6308 - 6319
Surgeons have unique in situ access to tumors enabling them to apply immunotherapies to resection margins as a means to prevent local recurrence. Here, we... 
MICROENVIRONMENT | ONCOLOGY | IMMUNE SUPPRESSION | MACROPHAGES | TUMOR-REGRESSION | INTERLEUKIN-10 | CANCER | IL-10 | CHEMOTHERAPY | RADIATION-THERAPY | ANTIGEN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
by Postow, Michael A and Sidlow, Robert and Hellmann, Matthew D
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 158 - 168
The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients... 
UNTREATED MELANOMA | METASTATIC MELANOMA | ALLOGRAFT-REJECTION | MEDICINE, GENERAL & INTERNAL | PREEXISTING AUTOIMMUNE DISORDERS | TUMOR-REGRESSION | INDUCED COLITIS | CELL TRANSPLANTATION | T-LYMPHOCYTE ANTIGEN-4 | SINGLE-ARM | PHASE-2 TRIAL | T-Lymphocytes - physiology | Antineoplastic Agents, Immunological - adverse effects | Immunotherapy - methods | Neoplasms - immunology | Humans | Antibodies, Monoclonal - adverse effects | Immunosuppressive Agents - adverse effects | Cell Cycle Checkpoints - immunology | Immunotherapy - adverse effects | Neoplasms - drug therapy | Practice | Hospital patients | Care and treatment | Research | Physicians | Immune system | Antigens | Immunoglobulins | Cytokines | Cytotoxicity | Systematic review | Metastasis | FDA approval | Patients | Cancer therapies | Side effects | Immune checkpoint | Lymphocytes | Immunotherapy | Ligands | Apoptosis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma
by Puzanov, Igor and Milhem, Mohammed M and Minor, David and Hamid, Omid and Li, Ai and Chen, Lisa and Chastain, Michael and Gorski, Kevin S and Anderson, Abraham and Chou, Jeffrey and Kaufman, Howard L and Andtbacka, Robert H.I
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 22, pp. 2619 - 2626
Purpose Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and efficacy of talimogene... 
CTLA-4 BLOCKADE | METASTATIC MELANOMA | ANTIGEN-4 BLOCKADE | COLONY-STIMULATING FACTOR | DENDRITIC CELLS | ONCOLOGY | IMMUNOTHERAPY | AUTOIMMUNITY | TUMOR-REGRESSION | CANCER | T-CELLS | T-Lymphocyte Subsets - immunology | Skin Neoplasms - therapy | Humans | Ipilimumab | Middle Aged | Male | Tumor Burden | Oncolytic Virotherapy - methods | Antibodies, Monoclonal - administration & dosage | Aged, 80 and over | Adult | Female | Aged | Oncolytic Viruses | Melanoma - therapy | Oncolytic Virotherapy - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
by Thomas J. Lynch and Igor Bondarenko and Alexander Luft and Piotr Serwatowski and Fabrice Barlesi and Raju Chacko and Martin Sebastian and Joel Neal and Haolan Lu and Jean-Marie Cuillerot and Martin Reck
Journal of Clinical Oncology, ISSN 0732-183X, 06/2012, Volume 30, Issue 17, pp. 2046 - 2054
Purpose Ipilimumab, which is an anti-cytotoxic T-cell lymphocyte-4 monoclonal antibody, showed a survival benefit in melanoma with adverse events (AEs) managed... 
TRIAL | METASTATIC MELANOMA | CTLA-4 BLOCKADE | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | IMMUNE-SYSTEM | ONCOLOGY | FAVORABLE PROGNOSIS | TUMOR-REGRESSION | ANTITUMOR IMMUNITY | PLUS CARBOPLATIN | CD8(+) T-CELLS | Lung Neoplasms - drug therapy | Double-Blind Method | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Proportional Hazards Models | Carboplatin - administration & dosage | Male | Treatment Outcome | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Aged, 80 and over | Placebos | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Paclitaxel - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
by Tran, Eric and Turcotte, Simon and Gros, Alena and Robbins, Paul F and Lu, Yong-Chen and Dudley, Mark E and Wunderlich, John R and Somerville, Robert P and Hogan, Katherine and Hinrichs, Christian S and Parkhurst, Maria R and Yang, James C and Rosenberg, Steven A
Science, ISSN 0036-8075, 2014, Volume 344, Issue 6184, pp. 641 - 645
Limited evidence exists that humans mount a mutation-specific T cell response to epithelial cancers. We used a whole-exomic-sequencing-based approach to... 
METASTATIC MELANOMA | RESPONSES | GENE | LUNG-CARCINOMA | IFN-GAMMA | MULTIDISCIPLINARY SCIENCES | IN-VIVO | TUMOR-REGRESSION | CD4(+) T-CELLS | ESTABLISHED MELANOMA | LYMPHOCYTES | Cholangiocarcinoma - therapy | Humans | Receptor, ErbB-2 - metabolism | Lymphocytes, Tumor-Infiltrating - transplantation | Th1 Cells - transplantation | CD4-Positive T-Lymphocytes - immunology | Exome | Bile Duct Neoplasms - therapy | Adoptive Transfer - methods | Adaptor Proteins, Signal Transducing - genetics | Cholangiocarcinoma - genetics | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Mutation | Clinical Trials, Phase II as Topic | Care and treatment | Epithelial cells | Immunotherapy | T cells | Health aspects | Methods | Cancer | Patients | Cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-alpha 2b in Advanced Melanoma
by Tarhini, AA and Lee, SJ and Li, XX and Rao, UNM and Nagarajan, A and Albertini, MR and Mitchell, JW and Wong, SJ and Taylor, MA and Laud, N and Truong, PV and Conry, RM and Kirkwood, JM
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2019, Volume 25, Issue 2, pp. 524 - 532
Purpose: Interferon-alpha favors a Th1 shift in immunity, and combining with ipilimumab (ipi) at 3 or 10 mg/kg may downregulate CTLA4-mediated suppressive... 
SURVIVAL | MULTICENTER | THERAPY | ONCOLOGY | IMMUNOTHERAPY | COMBINED NIVOLUMAB | TREMELIMUMAB | TUMOR-REGRESSION | EXPRESSION | CELL CARCINOMA | IFN-ALPHA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Targeting neoantigens to augment antitumour immunity
by Yarchoan, Mark and Johnson, Burles A and Lutz, Eric R and Laheru, Daniel A and Jaffee, Elizabeth M
Nature Reviews Cancer, ISSN 1474-175X, 04/2017, Volume 17, Issue 4, pp. 209 - 222
The past decade of cancer research has been marked by a growing appreciation of the role of immunity in cancer. Mutations in the tumour genome can cause... 
PLASMACYTOID DENDRITIC CELLS | GROWTH-FACTOR RECEPTOR | DOSE CYTARABINE | ONCOLOGY | PD-1 BLOCKADE | INDOLEAMINE 2,3-DIOXYGENASE | CYTOLYTIC T-LYMPHOCYTES | TUMOR-REGRESSION | CANCER-IMMUNOTHERAPY | HUMAN-PAPILLOMAVIRUS | CHECKPOINT BLOCKADE | Immunotherapy - methods | Neoplasms - therapy | Tumor Escape | Animals | Antigens, Neoplasm - immunology | Neoplasms - immunology | Humans | Tumor Microenvironment | T-Lymphocytes - immunology | Adoptive Transfer | Mutation | Precision Medicine | Care and treatment | Gene mutations | Immunotherapy | Innovations | Gene expression | Health aspects | Methods | Cancer | Proteins | Genomes | Immunity | Immunological tolerance | Tumors | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text MYC regulates the antitumor immune response through CD47 and PD-L1
by Casey, Stephanie C and Tong, Ling and Li, Yulin and Do, Rachel and Walz, Susanne and Fitzgerald, Kelly N and Gouw, Arvin M and Baylot, Virginie and Gütgemann, Ines and Eilers, Martin and Felsher, Dean W
Science, ISSN 0036-8075, 04/2016, Volume 352, Issue 6282, pp. 227 - 231
The MYC oncogene codes for a transcription factor that is overexpressed in many human cancers. Here we show that MYC regulates the expression of two immune... 
INACTIVATION | TARGET | STEM-CELLS | MULTIDISCIPLINARY SCIENCES | THROMBOSPONDIN-1 | C-MYC | TUMOR-REGRESSION | GENE-EXPRESSION | CD4(+) T-CELLS | LEUKEMIA | CANCER | CD47 Antigen - genetics | Promoter Regions, Genetic | RNA, Small Interfering - genetics | Jurkat Cells | Down-Regulation | Humans | Gene Expression Regulation, Neoplastic | Lymphoma - immunology | Lymphoma - genetics | B7-H1 Antigen - genetics | Proto-Oncogene Proteins c-myc - metabolism | Gene Knockdown Techniques | Cell Transformation, Neoplastic - immunology | Animals | Cell Transformation, Neoplastic - genetics | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Cell Line, Tumor | Immune Tolerance - genetics | Mice | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - immunology | Proto-Oncogene Proteins c-myc - genetics | Proteins | Gene expression | Immunotherapy | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy
by Repetto, Ombretta and De Re, Valli and De Paoli, Antonino and Belluco, Claudio and Alessandrini, Lara and Canzonieri, Vincenzo and Cannizzaro, Renato
Oncotarget, 2017, Volume 8, Issue 17, pp. 28328 - 28341
Gastric diseases | DIGE | Rectal proteomics | Rectal cancer | Tumor regression grade
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
by Hodi, F. Stephen and O'Day, Steven J and McDermott, David F and Weber, Robert W and Weber, Jeffrey S and Sosman, Jeffrey A and Haanen, John B and Gonzalez, Rene and Robert, Caroline and Schadendorf, Dirk and Hassel, Jessica C and Akerley, Wallace and van den Eertwegh, Alfons J.M and Lutzky, Jose and Lorigan, Paul and Vaubel, Julia M and Linette, Gerald P and Hogg, David and Ottensmeier, Christian H and Lebbé, Celeste and Peschel, Christian and Quirt, Ian and Clark, Joseph I and Wolchok, Jedd D and Tian, Jason and Yellin, Michael J and Nichol, Geoffrey M and Hoos, Axel and Urba, Walter J
The New England Journal of Medicine, ISSN 0028-4793, 08/2010, Volume 363, Issue 8, pp. 711 - 723
The authors treated 676 patients with metastatic melanoma with an antibody to CTLA-4 (ipilimumab), the antibody plus a gp100 vaccine, or the vaccine alone.... 
MEDICINE, GENERAL & INTERNAL | STAGE-IV MELANOMA | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | SOLID TUMORS | TUMOR-REGRESSION | DOUBLE-BLIND | T-LYMPHOCYTE ANTIGEN-4 | MALIGNANT-MELANOMA | CLINICAL-RESPONSE | ADVERSE EVENTS | Skin Neoplasms - pathology | Antigens, CD - immunology | Double-Blind Method | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Antibodies, Monoclonal - therapeutic use | Cancer Vaccines - adverse effects | Male | Treatment Outcome | Combined Modality Therapy | Melanoma - secondary | CTLA-4 Antigen | Cancer Vaccines - therapeutic use | Melanoma - drug therapy | Female | Melanoma - therapy | Melanoma - mortality | Usage | Melanoma | Monoclonal antibodies | Research | Drug therapy | T cells | Health aspects | Vaccines | Cytokines | Autoimmune diseases | Skin cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights